Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
Anti-PD-1 antibodies offer potentially life-saving treatment for some cancer patients, but their chronic administration generates high and ever-increasing costs. Despite licensing for long-term use, optimal treatment duration is unknown. We challenge the need for long-term treatment duration, using evidence from melanoma research, both published and in process.
With an ever-growing body of oncology research, BJC Reviews seek to summarise and condense that information into thought-provoking commentaries. They cover a broad remit of oncology research, from the cellular and molecular events that underpin tumorigenesis and disease progression, to existing and emerging therapeutics and clinical cancer management. Our recent review articles are presented for you in this evolving Collection; we hope you enjoy reading them.